New trends of progestins treatment of endometriosis

Stefano Angioni; Vito Cofelice; Alessandro Pontis; Raffaele Tinelli; Razvan Socolov; Răzvan Socolov

doi:10.3109/09513590.2014.950646

New trends of progestins treatment of endometriosis

Stefano Angioni, Vito Cofelice, Alessandro Pontis, Raffaele Tinelli, Razvan Socolov, Răzvan Socolov

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2014 · vol. 30(11) , pp. 769–773 · doi:10.3109/09513590.2014.950646 · PMID:25144122 · W1994550648

review OA: closed CC0 ⤵ 51 in-corpus citations

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review presents clinical studies on new trends in progestin treatment for symptomatic endometriosis, focusing on developing better-tolerated drugs and administration routes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The management of endometriosis with OC or progestins is generally safe, effective and well-tolerated and should constitute the first line of medical treatment in symptomatic patients who do not want to have children. Progestins, synthetic progestational agents, have been used in the management of symptomatic endometriosis both as primary therapy and as an adjunct to surgical time. A variety of oral agents have been employed in this regard and investigators have demonstrated differing degrees of benefit. The lack of a standardized instrument to evaluate painful symptoms makes comparative analysis more difficult. Concern about efficacy and side effect has pushed the research on the development of new well-tolerated drugs and to develop new administration routes to minimize general side effects. Aim of the present review is to present the results of clinical studies on new trends of progestins in the treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Intrauterine Devices, Medicated Progestins Endometriosis Female Humans Progestins Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (50)

Source provenance

europepmc: last seen: 2026-06-11T06:19:48.454388+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-05-13T22:18:15.805398+00:00

License: CC0 · commercial use OK

[1] A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program via openalex

[2] A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex

[3] Alexithymia in Women with Deep Endometriosis? A Pilot Study via openalex

[4] Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis via openalex

[5] Anti-Müllerian hormone trend after laparoscopic surgery in women with ovarian endometrioma via openalex

[6] Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study via openalex

[7] Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis via openalex

[8] Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex

[9] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex

[10] Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study via openalex

[11] Effect of norethindrone acetate in the treatment of symptomatic endometriosis. via openalex

[12] Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium via openalex

[13] Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study via openalex

[14] Eutopic Endometrium From Women With Endometriosis Shows Altered Ultrastructure and Glycosylation Compared to That From Healthy Controls—A Pilot Observational Study via openalex

[15] Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis via openalex

[16] Peritoneal adhesions in human and veterinary medicine: from pathogenesis to therapy. A review via openalex

[17] Rectal perforation from endometriosis in pregnancy: Case report and literature review via openalex

[18] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex

[19] Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current classification system via openalex

[20] Single Port Access Laparoscopy (SPAL) for endometrioma excision via openalex

[21] The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex

[22] The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease via openalex

[23] The value of serological markers in the diagnosis and prognosis of endometriosis: a prospective case–control study via openalex

[24] Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis via openalex

[25] W4200472726 via openalex

[26] W1978085719 via openalex

[27] W1990483217 via openalex

[28] W2023365171 via openalex

[29] W2025633250 via openalex

[30] W2085433217 via openalex

[31] W2101417341 via openalex

[32] W2123134517 via openalex

[33] W2124584160 via openalex

[34] W2126023204 via openalex

[35] W2153607635 via openalex

[36] W18374401 via openalex